Disclosure The authors declare that they have no affiliation with, or involvement in, any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript
GLP-1 receptor agonists slow digestion and increase feelings of fullness, categorizing them as anti-obesity medications (AOMs)
The subcutaneous injections available in the United States are dulaglutide (Trulicity, Eli Lilly, for type 2 diabetes), liraglutide (Victoza, Novo Nordisk, for type 2 diabetes), semaglutide (Ozempic, Novo Nordisk, for type 2 diabetes and Wegovy, for weight loss), tirzepatide (Mounjaro, Eli Lilly, for type 2 diabetes), and Zepbound (Eli Lilly, for weight loss)
Efficacy and safety of meal-time administration of short-acting exenatide for glycemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
And the weight loss curve had not yet plateaued, meaning participants were likely to lose even more with continued treatment
Sermorelin Sermorelin stimulates natural growth hormone production and is FDA-approved, but only for diagnosing and treating growth hormone deficiency in children
